PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110
PainReform Ltd. - Ordinary Shares (PRFX)
Company Research
Source: GlobeNewswire
TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, non-opiate, post-surgical pain relief. The Company conducted comprehensive in vitro studies to assess the impact of PRF-110 on both non-absorbable and resorbable sutures. Given that suture materials are often in proximity to the PRF-110 oily solution following surgery, it was critical to evaluate whether PRF-110 would affect the mechanical properties of these sutures. The mechanical integrity, including breaking force and elongation, of PROLENE™ non-absorbable sutures and Vicryl™ resorbable sutures was tested at the outset (time zero) and after 14 days, with comparisons made to a control group.
Show less
Read more
Impact Snapshot
Event Time:
PRFX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRFX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRFX alerts
High impacting PainReform Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
PRFX
News
- PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110 [Yahoo! Finance]Yahoo! Finance
- PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110GlobeNewswire
- PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial [Yahoo! Finance]Yahoo! Finance
- PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical TrialGlobeNewswire
PRFX
Sec Filings
- 1/2/25 - Form 424B5
- 1/2/25 - Form 6-K
- 12/27/24 - Form 6-K
- PRFX's page on the SEC website